Physician profile
Gabriel E Gonzalez
NPI 1033102447
$1,321.22
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $11.07 · 2022: $65.83 · 2023: $933 · 2024: $18.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $857 · Education: $94.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $857.03 |
| Education | $94.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $224.33 | 2019-2023 | Dupixent |
| Glaxosmithkline, LLC. | $204.93 | 2019-2023 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $174.18 | 2022-2023 | Fasenra, Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $105.41 | 2023 | Hyqvia |
| Sanofi-Aventis U.S. LLC | $99.99 | 2019 | |
| Genzyme Corporation | $82.49 | 2019-2023 | |
| Csl Behring | $71.26 | 2019-2023 | Hizentra, Kcentra |
| Grifols USA, LLC | $60.97 | 2023 | Xembify, Prolastin-C Liquid |
| Kaleo, INC. | $54.28 | 2019-2023 | Auvi-Q |
| Biocryst US Sales Co., LLC | $46.86 | 2023 | Orladeyo |
| Amgen INC. | $38.19 | 2022 | |
| Pfizer INC. | $38.08 | 2023 | |
| Alk-Abello, INC | $35.92 | 2023 | Grastek, Ragwitek, Odactra |
| Abbvie INC. | $34.10 | 2023-2024 | |
| Pharming Healthcare, INC. | $27.09 | 2023 | Ruconest |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $23.14 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.